Journal
VACCINES
Volume 9, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9040345
Keywords
chikungunya virus; immune competent; mouse model; DNA vaccine; virus-like particle
Categories
Funding
- University of South Alabama College of Medicine Intramural Grants Program
Ask authors/readers for more resources
The study suggests that DNA launched VLP vaccines may have potential in preventing CHIKV infection compared to live attenuated vaccines, and gender differences in viral RNA loads in male and female mice were discovered, impacting the interpretation of vaccine efficacy and potentially influencing future CHIKV vaccine development.
Chikungunya virus (CHIKV) infection can result in chronic and debilitating arthralgia affecting humans in tropical and subtropical regions around the world, yet there are no licensed vaccines to prevent infection. DNA launched virus like particle (VLP) vaccines represent a potentially safer alternative to traditional live-attenuated vaccines; however, fully characterized immunocompetent mouse models which appropriately include both male and female animals for preclinical evaluation of these, and other, vaccine platforms are lacking. Utilizing virus stocks engineered to express mutations reported to enhance CHIKV virulence in mice, infection of male and female immunocompetent mice was evaluated, and the resulting model utilized to assess the efficacy of candidate DNA launched CHIKV VLP vaccines. Results demonstrate the potential utility of DNA launched VLP vaccines in comparison to a live attenuated CHIKV vaccine and identify gender differences in viral RNA loads that impact interpretation of vaccine efficacy and may have important implications for future CHIKV vaccine development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available